Export 2633 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
J. Smith, Thompson, D., Whitcup, S., Suhler, E., Clarke, G., Robinson, M., and Baron, K., The treatment of JRA-associated uveitis with Etanercept, 2002.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial, Proceedings of the National Academy of Science USA, vol. 96, pp. 7462-66, 1999.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial., Proc Natl Acad Sci U S A, vol. 96, no. 13, pp. 7462-6, 1999.
E. Atallah, Bylow, K., Troy, J., and Saber, W., Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT)., Curr Hematol Malig Rep, vol. 9, no. 1, pp. 57-65, 2014.
E. Atallah, Bylow, K., Troy, J., and W, S., Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): the Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT), Curr Hematol Malig Rep, vol. 9, pp. 57-65, 2014.
V. DA, Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute; 5-year follow-up report,, J Clin Oncol, vol. 15, 1997.
J. M. Sorensen, Vena, D. A., Fallavollita, A., Chun, H. G., and Cheson, B. D., Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report., J Clin Oncol, vol. 15, no. 2, pp. 458-65, 1997.
K. A. Holtz, Szefer, E., Noonan, V. K., Kwon, B. K., and Mills, P. B., Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study., Spinal Cord, vol. 56, no. 12, pp. 1176-1183, 2018.
O. Gasser, Bihl, F., Sanghavi, S., Rinaldo, C., Rowe, D., Hess, C., Stablein, D., Roland, M., Stock, P., and Brander, C., Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation., Am J Transplant, vol. 9, no. 4, pp. 794-803, 2009.
O. Gasser, Bihl, F., Sanghavi, S., Rinaldo, C., Rowe, D., Hess, C., Stablein, D., Roland, M., Stock, P., and Brander, C., Treatment-Dependent Loss of Polyfunctional Cd8+ T-Cell Responses in HIV-Infected Kidney Transplant Recipients Is Associated with Herpesvirus Reactivation, Am J Transplant, vol. 9, pp. 794-803, 2009.
A. Veitz-Keenan, Barna, J. A., Strober, B., Matthews, A. G., Collie, D., Vena, D., Curro, F. A., and Thompson, V. P., Treatments for Hypersensitive Noncarious Cervical Lesions: A Practitioners Engaged in Applied Research and Learning (PEARL) Network Randomized Clinical Effectiveness Study, J Am Dent Assoc, vol. 144, pp. 495-506, 2013.
A. Veitz-Keenan, Barna, J. Ann, Strober, B., Matthews, A. G., Collie, D., Vena, D., Curro, F. A., and Thompson, V. P., Treatments for hypersensitive noncarious cervical lesions: a Practitioners Engaged in Applied Research and Learning (PEARL) Network randomized clinical effectiveness study., J Am Dent Assoc, vol. 144, no. 5, pp. 495-506, 2013.
S. DM, Trend in immunosuppressive therapy: A report of the North American Pediatric Cooperative Study (NAPRTCS), 1998.
M. Benfield, Stablein, D., and Tejani, A., Trends in immunosuppressive therapy: A report of the North American Pediatric Cooperative Study (NAPRTCS), Pediatr Transplantation, vol. 3, pp. 27-32, 1999.
M. R. Benfield, Stablein, D., and Tejani, A., Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)., Pediatr Transplant, vol. 3, no. 1, pp. 27-32, 1999.
R. Wood, Sicherer, S., Stablein, D., Jones, S., Burks, A., Liu, A., Fleischer, D., Leung, D., Lindblad, R., Sampson, H., and CoFAR), Co.F. A. R. (, Trends in Milk, Egg, and Peanut IgE Levels Over Time in an Observational Study of Infants with Food Allergy (COFAR2): One Year Follow Up, Washington DC: , 2009.
E. M. G. Esterli JR, Trial of calcium for preeclampsia prevention (CPEP): rationale, design and methods,, Control Clin Trials, vol. 17, pp. 442-69, 1996.
R. J. Levine, Esterlitz, J. R., Raymond, E. G., DerSimonian, R., Hauth, J. C., Ben Curet, L., Sibai, B. M., Catalano, P. M., Morris, C. D., Clemens, J. D., Ewell, M. G., Friedman, S. A., Goldenberg, R. L., Jacobson, S. L., Joffe, G. M., Klebanoff, M. A., Petrulis, A. S., and Rigau-Perez, J. G., Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods., Control Clin Trials, vol. 17, no. 5, pp. 442-69, 1996.
R. J. Levine, Hauth, J. C., Curet, L. B., Sibai, B. M., Catalano, P. M., Morris, C. D., DerSimonian, R., Esterlitz, J. R., Raymond, E. G., Bild, D. E., Clemens, J. D., and Cutler, J. A., Trial of calcium to prevent preeclampsia., N Engl J Med, vol. 337, no. 2, pp. 69-76, 1997.
S. Shenoy, Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., Kasow, K. A., Leung, K., Andreansky, M., Bhatia, M., Dalal, J., Haines, H., Jaroscak, J., Lazarus, H. M., Levine, J. E., Krishnamurti, L., Margolis, D., Megason, G. C., Yu, L. C., Pulsipher, M. A., Gersten, I., DiFronzo, N., Horowitz, M. M., Walters, M. C., and Kamani, N., A trial of unrelated donor marrow transplantation for children with severe sickle cell disease., Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
M. Allen, Israel, H., Rybczyk, K., Pugliese, M. A., Loughran, K., Wagner, L., and Erb, S., Trial-related discrimination in HIV vaccine clinical trials., AIDS Res Hum Retroviruses, vol. 17, no. 8, pp. 667-74, 2001.
M. A. Allen, Israel, H. A., Rybczyk, K., Pugliese, M., Loughran, K., Wagner, L., and Erb, S., Trial-related discrimination in HIV vaccine clinical trials, AIDS Res HumRetroviruses, vol. 17, pp. 667-74, 2001.
M. J. Mulligan, Stapleton, J. T., Keitel, W. A., Frey, S. E., Chen, W. H., Rouphael, N., Edupuganti, S., Beck, A., Winokur, P. L., Sahly, H. M. El, Patel, S. M., Atmar, R. L., Graham, I., Anderson, E., El-Kamary, S. S., Pasetti, M. F., Sztein, M. B., Hill, H., and Goll, J. B., Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial., Vaccine, vol. 35, no. 36, pp. 4730-4737, 2017.
S. P. Emery, Levine, R. J., Quan, C., Ewell, M., England, L. J., Yu, K. F., and Catalano, M., Twenty-Four Hour Urine Insulin as a Measure of Hyperinsulinaemia/Insulin Resistance Before Onset of Pre-Eclampsia and Gestational Hypertension, BJOG, vol. 112, pp. 1471-1528, 2005.
S. P. Emery, Levine, R. J., Qian, C., Ewell, M. G., England, L. J., Yu, K. F., and Catalano, P. M., Twenty-four-hour urine insulin as a measure of hyperinsulinaemia/insulin resistance before onset of pre-eclampsia and gestational hypertension., BJOG, vol. 112, no. 11, pp. 1479-85, 2005.